Coronavirus (COVID-19)
Learn more
April 26, 2017
Sponsor: Janssen Research & Development, LLC
Number: ET743-OVC-3006
The purpose of this study is to assess the efficacy and safety of Trabectedin+DOXIL as a third-line chemotherapy regimen in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy. Third line chemotherapy regimens are treatments given when both initial treatment (first-line therapy) and subsequent treatment (second-line therapy) don’t work, or stop working.
Who’s eligible:
Available at: The Hospital of Central Connecticut, Hartford Hospital.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.